MetLife Investment Management’s Clovis Oncology, Inc. CLVS Stock Holding History

MetLife Investment Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-43,789	Closed	-$119K	–	2788
2021 Q4	$119K	Buy	43,789 +23,024	+111%	+$85.1K	﹤0.01%	2344
2021 Q3	$92.6K	Sell	20,765 -17,813	-46%	-$85.8K	﹤0.01%	2471
2021 Q2	$224K	Buy	38,578 +25,827	+203%	+$151K	﹤0.01%	2093
2021 Q1	$89.5K	Sell	12,751 -24,880	-66%	-$167K	﹤0.01%	2256
2020 Q4	$181K	Buy	37,631 +3,655	+11%	+$18.5K	﹤0.01%	2031
2020 Q3	$198K	Hold	33,976	–	–	﹤0.01%	1870
2020 Q2	$229K	Buy	33,976 +12,009	+55%	+$90.9K	﹤0.01%	1825
2020 Q1	$140K	Hold	21,967	–	–	﹤0.01%	1884
2019 Q4	$229K	Hold	21,967	–	–	﹤0.01%	1909
2019 Q3	$86.3K	Hold	21,967	–	–	﹤0.01%	2316
2019 Q2	$327K	Hold	21,967	–	–	﹤0.01%	1744
2019 Q1	$545K	Hold	21,967	–	–	0.01%	1400
2018 Q4	$395K	Hold	21,967	–	–	﹤0.01%	1517
2018 Q3	$645K	Hold	21,967	–	–	0.01%	1369
2018 Q2	$999K	Buy	21,967 +1,764	+9%	+$85.8K	0.01%	1015
2018 Q1	$1.07M	Hold	20,203	–	–	0.01%	978
2017 Q4	$1.37M	Buy	+20,203	New	+$1.41M	0.02%	905

Other funds holding CLVS

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

MetLife Investment Management's CLVS Position: Q1 2022 in Review

MetLife Investment Management sold out of Clovis Oncology, Inc. (CLVS) in Q1 2022, closing a stake of 43,789 shares — an estimated $119K sold.

MetLife Investment Management first reported a position in CLVS in Q4 2017 and held it in 17 quarters. The position peaked at $1.37M in Q4 2017. 153 funds tracked by Wall St. Rank hold CLVS as of Q1 2022.

MetLife Investment Management reported no remaining Clovis Oncology, Inc. position as of Q1 2022 after selling out during the quarter.
MetLife Investment Management sold 43,789 Clovis Oncology, Inc. shares in Q1 2022, an estimated $119K.
MetLife Investment Management first reported a position in Clovis Oncology, Inc. in Q4 2017 and held it in 17 quarters.
MetLife Investment Management's Clovis Oncology, Inc. position peaked at $1.37M in Q4 2017.
153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2022.

Based on MetLife Investment Management's 13F filing for Q1 2022, filed 12 May 2022.